свидетельство о рождении ребенка 2011 года рождения
Главное меню:
Интересное
свидетельство о рождении ребенка 2011 года рождения, Management of Menopausal Symptoms: A Review - JAMA Network, Non-hormonal management of vasomotor symptoms of menopause, Assessment of women’s treatment preferences for vasomotor symptoms due , A New Era in Menopause Management? - JAMA Network, Management of Menopausal Symptoms: A Review.,JAMA - X-MOL, The management of vasomotor symptoms of menopause (VMS) with menopausal , Management of Menopausal Symptoms: A Review. - Read by QxMD.
Sebastian Geraci, resident physician, Satu Kuokkanen, clinical associate professor, Erika Banks, chairNew York University Langone Hospital, Long Island, Mineola, NY, USACorrespondence to: S Geraci sebastian.geraci{at}nyulangone.orgA new treatment option for women unable to take hormone replacement therapyUp to 80% of women experience vasomotor symptoms, including hot flushes and night sweats, during menopausal transition.1234567 These symptoms can persist for years before and after menopause, substantially impacting quality of life by impairing sleep, mood, and cognitive functioning.23456789101112 Approximately 32-46% of women describe their vasomotor symptoms as moderate to severe and would warrant treatment; studies suggest that the median total length of vasomotor symptoms is 7.4 years.4569 An effective treatment of vasomotor symptoms is hormonal therapy, but this treatment is not appropriate for everyone and only about 10% of women worldwide with vasomotor symptoms report using hormonal therapy.23561011131415 Contraindications to hormonal therapy and concerns for adverse effects with prolonged hormonal therapy use may contribute to its low use.2345679 Non-hormonal alternatives to manage vasomotor symptoms are available but these alternatives are generally considered less efficacious than hormonal therapy.6910111314 Furthermore, before 2023, paroxetine was the … , This narrative review discusses treatments for women with bothersome vasomotor symptoms (hot flashes, night sweats, or both) and genitourinary syndrome of menopause (genitourinary symptoms), which include hormonal and nonhormonal options., A new treatment option for women unable to take hormone replacement therapy Up to 80% of women experience vasomotor symptoms, including hot flushes and night sweats, during menopausal transition.1234567 These symptoms can persist for years before and after menopause, substantially impacting quality of life by impairing sleep, mood, and cognitive functioning.23456789101112 Approximately 32-46% .
Hormone and non-hormone treatments are available to reduce vasomotor symptoms (hot flashes and night sweats) due to menopause. We conducted an online survey of 467 women with moderate to very severe vasomotor symptoms during perimenopause or postmenopause to learn what treatment attributes are most important to women when selecting from among the available therapies and how much women were , The drug being advertised, fezolinetant, was the first novel drug specifically for vasomotor symptom (VMS) management to come to market since estrogens became commercially available in the 1930s. This newfound attention to midlife women’s health is noteworthy given that menopause is a universal life event for more than half the global population., Conclusions and Relevance During the menopausal transition, approximately 50% to 75% of women have vasomotor symptoms and GSM symptoms. Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms and GSM symptoms, but nonhormonal medications (such as paroxetine and venlafaxine) also can be effective., Vasomotor symptoms (VMS) result from menopausal hypoestrogenism with subsequent instability of central thermoregulation. VMS cause stress and decreased QOL. Menopausal hormone therapy (MHT) significantly alleviates VMS when compared to placebo or other available non-hormonal options., OBSERVATIONS: Vasomotor symptoms typically last more than 7 years and GSM is often chronic. Efficacious treatments for women with bothersome vasomotor symptoms or GSM symptoms include hormonal and nonhormonal options. Systemic estrogen alone or combined with a progestogen reduces the frequency of vasomotor symptoms by approximately 75%., Key Points Question What are the efficacy and safety of elinzanetant, 120 mg, in postmenopausal individuals with moderate to severe vasomotor symptoms (VMS)? Findings In 2 pivotal phase 3 clinical trials, elinzanetant demonstrated statistically significant reductions in VMS frequency and severity vs placebo. Elinzanetant also significantly improved sleep disturbances and menopause-related .